LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...
March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate ...
Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...
A new study offers hope in the fight against flesh-eating fungus infections. Researchers have discovered a promising antibody ...
Q4 2024 Earnings Call Transcript March 20, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.05, ...
SUZHOU, China I March 23, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer ...
Asian News International on MSN5d
Antibody-based therapy several notches closer to treat lethal mucormycosis: StudyMucormycosis, a fungus infection caused by Mucorales, has a high mortality rates in those with weakened immune systems and ...
Results of the first phase of the ANRS VRI06 trial showed a good safety profile and strong immunogenicity of These immune responses mobilized both antibody- and cell-mediated immunity and ...
Results of the first phase of the ANRS VRI06 trial showed a good safety profile and strong immunogenicity of CD40.HIVRI.Env (AMV.HIVRI). These immune responses mobilized both antibody- and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback